GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (OTCPK:ONCSQ) » Definitions » ROC (Joel Greenblatt) %
中文

OncoSec Medical (OncoSec Medical) ROC (Joel Greenblatt) % : -854.47% (As of Jan. 2023)


View and export this data going back to 1986. Start your Free Trial

What is OncoSec Medical ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. OncoSec Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2023 was -854.47%.

The historical rank and industry rank for OncoSec Medical's ROC (Joel Greenblatt) % or its related term are showing as below:

ONCSQ's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -339.22
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

OncoSec Medical's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


OncoSec Medical ROC (Joel Greenblatt) % Historical Data

The historical data trend for OncoSec Medical's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical ROC (Joel Greenblatt) % Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,129.27 -2,635.70 -1,106.52 -724.07 -623.90

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -636.28 -630.71 -567.35 -612.81 -854.47

Competitive Comparison of OncoSec Medical's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, OncoSec Medical's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's ROC (Joel Greenblatt) % falls into.



OncoSec Medical ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Oct. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.903) - (5.027 + 0 + 0.245)
=-2.369

Working Capital(Q: Jan. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.759) - (5.778 + 0 + 0.115)
=-3.134

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of OncoSec Medical for the quarter that ended in Jan. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Jan. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Oct. 2022  Q: Jan. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-27.296/( ( (4.865 + max(-2.369, 0)) + (1.524 + max(-3.134, 0)) )/ 2 )
=-27.296/( ( 4.865 + 1.524 )/ 2 )
=-27.296/3.1945
=-854.47 %

Note: The EBIT data used here is four times the quarterly (Jan. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSec Medical  (OTCPK:ONCSQ) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


OncoSec Medical ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical (OncoSec Medical) Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
Executives
Robert J Delaversano officer: Principal Accounting Officer 217 W. MAIN STREET, SOMERVILLE NJ 08876
Spahr Stephany Foster director C/O ONCOSEC MEDICAL, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Robert H. Arch officer: President and CEO C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
George Chi officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Lin Shi director 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Yuhang Zhao director 6 HORTON DR., CHESTER NJ 07930
Brian A Leuthner officer: Chief Operating Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Daniel J. O'connor director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
China Grand Pharmaceutical & Healthcare Holdings Ltd 10 percent owner, other: See Remarks UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Alpha Holdings, Inc. director, 10 percent owner GANGNAM-GU APGUJEONG-RO 62-GIL 17-10, SEOUL M5 06016
Kellie Malloy Foerter officer: Chief Operating Officer C/O ONCOSEC MEDICAL INCORPORATED, 24 N. MAIN STREET, PENNINGTON NJ 08534-2218
Herbert Kim Lyerly director C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Chao Zhou director UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Grand Decade Developments Ltd 10 percent owner, other: See Remarks UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000

OncoSec Medical (OncoSec Medical) Headlines

From GuruFocus

OncoSec Provides Leadership Update

By PRNewswire PRNewswire 08-16-2021

OncoSec Announces Changes to its Board of Directors

By PRNewswire PRNewswire 12-17-2021